European Archives - Page 280 of 1235 - European Medical Journal

Skin Microbiome and Acne: Microbial Imbalances and Impact

Join dermatology experts Thomas Dirschka, Alison Layton, and Marco Rocha in this engaging audio recap of the article as they explore the…

Orange lungs on yellow background

AstraZeneca supports first asthma and COPD breakthrough in 50 years

Research supported by AstraZeneca has demonstrated that a single dose of benralizumab significantly reduces treatment failure rates – by four times compared to traditional steroid tablets.

Evolving Patient Centered Therapies for Metastatic NSCLC

The metastatic non-small cell lung cancer (mNSCLC) treatment landscape has vastly expanded over the past two decades as a result of…

AI Voice Analysis Detects Early Parkinson’s with 99% Accuracy

AI voice analysis shows 99% accuracy in detecting Parkinson’s disease early, paving the way for better patient care.

Alternative LDL Lowering Strategy as Effective as Statins for Atherosclerosis

Alternative LDL cholesterol-lowering strategy offers similar outcomes to statins, with fewer side effects and better safety.

HIV Then and Now: Advances in Immunity and Vaccination

This week, Jonathan welcomes Mark Connors to explore advancements in HIV vaccine technology and the progress in global understanding of HIV since the 1980s.

Reduced-Dose Steroids Linked to Higher Relapse Risk in ANCA-Associated Vasculitis

Reduced-dose steroids increase relapse and progression risk in ANCA-associated vasculitis, particularly in rituximab-treated patients, study shows.

PCOS Associated with Advanced Maternal Age

Women with polycystic ovary syndrome (PCOS) have fewer children and give birth later in life compared to women without PCOS.

No Survival Benefit for Chemoradiotherapy in Oesophageal Cancer

A new study comparing treatment strategies for stage T2N0M0 oesophageal cancer has revealed no significant survival advantage for patients receiving neoadjuvant chemoradiotherapy followed by surgery.

Nirmatrelvir/Ritonavir Alleviates COVID-19 Symptoms in High-Risk Patients

Nirmatrelvir/ritonavir reduced hospitalisations, symptom duration, and healthcare resource utilisation in high-risk, unvaccinated adults with mild-to-moderate COVID-19.